Amplia Therapeutics Limited (ASX: ATX)
Health Care · Biotechnology · AU
AU$0.08
-23.81% today · -44.8% 1Y
Amplia Therapeutics Limited (ASX: ATX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $28.57M and employs 8 people.
Over the last twelve months the share price has lost 44.8%, trading between 0.08 and 0.28.
Tweenvest scores Amplia Therapeutics Limited across four factors: quality 42/100, value 45/100. Its strongest factor is value.
ATX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $28.57M
- Revenue (TTM)
- $3.29M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- -0.33
- 52-week high
- AU$0.28
- 52-week low
- AU$0.08
- Avg volume (3M)
- —
- Shares outstanding
- 513.31M
- Employees
- 8
- Next earnings
- —
About Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
- ISIN
- AU0000023822
- Founded
- 2000
- Listed since
- Dec 19, 2013
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Quratis Inc.KOSDAQ: A348080 | $29.12M | ₩3,310.00 | -11.50% |
| Microbix Biosystems Inc.TSX: MBX | $29.05M | CA$0.30 | -3.23% |
| CEL-SCI CorporationNYSEAM: CVM | $28.85M | $1.64 | +1.86% |
| TransCode Therapeutics, Inc.NasdaqCM: RNAZ | $28.78M | $1.70 | -8.60% |
| NextCure, Inc.NasdaqGS: NXTC | $28.56M | $6.24 | -13.09% |
| Intervacc AB (publ)OM: IVACC | $28.25M | Skr0.82 | -7.44% |
| Matricelf LtdTASE: MTLF | $27.79M | ₪2.60 | +4.20% |
| Zenotech Laboratories LimitedBSE: 532039 | $27.69M | Rs43.06 | -0.02% |
Figures last refreshed Oct 18, 2026.